{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:52:04Z","timestamp":1792324324529,"version":"4.4.0"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL82774"],"award-info":[{"award-number":["HL82774"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL110764"],"award-info":[{"award-number":["HL110764"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK104114"],"award-info":[{"award-number":["DK104114"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL130233"],"award-info":[{"award-number":["HL130233"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL131460"],"award-info":[{"award-number":["HL131460"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK113775"],"award-info":[{"award-number":["DK113775"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.pharmthera.2020.107709","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T01:07:24Z","timestamp":1603156044000},"page":"107709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":252,"special_numbering":"C","title":["Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint"],"prefix":"10.1016","volume":"219","author":[{"given":"TingTing","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiZhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoFeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107709_bb0005","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2008.21.3017","article-title":"Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin\u2019s lymphoma","volume":"27","author":"Advani","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ni792","article-title":"The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells","volume":"3","author":"Ahonen","year":"2002","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00228-017-2362-8","article-title":"Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases","volume":"74","author":"Albach","year":"2018","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.178.2.669","article-title":"CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40","volume":"178","author":"Alderson","year":"1993","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0025","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/eji.201444941","article-title":"Interaction of CD154 with different receptors and its role in bidirectional signals","volume":"45","author":"Alturaihi","year":"2015","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0030","doi-asserted-by":"crossref","first-page":"11226","DOI":"10.1074\/jbc.M110.208215","article-title":"Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation","volume":"286","author":"An","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0035","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1172\/JCI28796","article-title":"CD40 induces macrophage anti-Toxoplasma gondii activity by triggering autophagy-dependent fusion of pathogen-containing vacuoles and lysosomes","volume":"116","author":"Andrade","year":"2006","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0040","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000028962.04520.01","article-title":"Platelet-derived CD40L: the switch-hitting player of cardiovascular disease","volume":"106","author":"Andr\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism","volume":"8","author":"Andr\u00e9","year":"2002","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0050","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.4049\/jimmunol.164.7.3689","article-title":"Role of CD40 ligand and CD28 in induction and maintenance of antiviral CD8+ effector T cell responses","volume":"164","author":"Andreasen","year":"2000","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/bdd.2130","article-title":"Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis","volume":"39","author":"Anil Kumar","year":"2018","journal-title":"Biopharmaceutics & Drug Disposition"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/357080a0","article-title":"Molecular and biological characterization of a murine ligand for CD40","volume":"357","author":"Armitage","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0065","doi-asserted-by":"crossref","first-page":"e1468956","DOI":"10.1080\/2162402X.2018.1468956","article-title":"Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma","volume":"7","author":"Bajor","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0070","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1021\/bi00006a003","article-title":"Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction","volume":"34","author":"Bajorath","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0075","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1021\/bi00031a009","article-title":"Analysis of gp39\/CD40 interactions using molecular models and site-directed mutagenesis","volume":"34","author":"Bajorath","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0080","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0085","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2012.09251.x","article-title":"A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma","volume":"159","author":"Bensinger","year":"2012","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0095","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/eji.200535483","article-title":"Rapid CD40-mediated rescue from CD95-induced apoptosis requires TNFR-associated factor-6 and PI3K","volume":"36","author":"Benson","year":"2006","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0100","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.4049\/jimmunol.177.11.7772","article-title":"Gut IgA class switch recombination in the absence of CD40 does not occur in the lamina propria and is independent of germinal centers","volume":"177","author":"Bergqvist","year":"2006","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(02)00057-4","article-title":"Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys","volume":"174","author":"Boon","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0110","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0115","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1126\/science.1072615","article-title":"A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory","volume":"297","author":"Bourgeois","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0120","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1084\/jem.192.11.1545","article-title":"Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production","volume":"192","author":"Breitfeld","year":"2000","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0125","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/blood.V92.11.4238","article-title":"Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor","volume":"92","author":"Brossart","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0130","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/jnci\/94.18.1381","article-title":"The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis","volume":"94","author":"Bugajska","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0135","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood.V93.6.1992.406k23_1992_2002","article-title":"CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells","volume":"93","author":"Buhmann","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0140","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3109\/10428194.2012.681655","article-title":"Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia","volume":"53","author":"Byrd","year":"2012","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0145","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaci.2011.10.026","article-title":"Condino-Neto A. Dendritic cells from X-linked hyper-IgM patients present impaired responses to Candida albicans and Paracoccidioides brasiliensis","volume":"129","author":"Cabral-Marques","year":"2012","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0150","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jaci.2018.02.026","article-title":"CD40 ligand deficiency causes functional defects of peripheral neutrophils that are improved by exogenous IFN-\u03b3","volume":"142","author":"Cabral-Marques","year":"2018","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0155","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jaci.2016.07.018","article-title":"Human CD40 ligand deficiency dysregulates the macrophage transcriptome causing functional defects that are improved by exogenous IFN-\u03b3","volume":"139","author":"Cabral-Marques","year":"2017","journal-title":"The Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0160","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1074-7613(00)80436-7","article-title":"CD40 ligand is required for protective cell-mediated immunity to Leishmania major","volume":"4","author":"Campbell","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0165","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2008-01-130252","article-title":"Human CD14hi monocytes and myeloid dendritic cells provide a cell contact-dependent costimulatory signal for early CD40 ligand expression","volume":"117","author":"Chakrabarty","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0170","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0175","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1038\/s41467-019-12446-5","article-title":"CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance","volume":"10","author":"Chen","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0180","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1538-7836.2010.03837.x","article-title":"CD40 ligand shedding is regulated by interaction between matrix metalloproteinase-2 and platelet integrin alpha(IIb)beta(3)","volume":"8","author":"Choi","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0185","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1158\/2326-6066.CIR-13-0070","article-title":"Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7\/4 phase I trial","volume":"2","author":"Chowdhury","year":"2014","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0190","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jlb.67.5.607","article-title":"The critical role of CD40\/CD40L in the CD4-dependent generation of CD8+ T cell immunity","volume":"67","author":"Clarke","year":"2000","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0195","doi-asserted-by":"crossref","first-page":"32801","DOI":"10.1074\/jbc.M209993200","article-title":"Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling","volume":"278","author":"Contin","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0200","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/CJI.0b013e3182a80237","article-title":"Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma","volume":"36","author":"Creelan","year":"2013","journal-title":"Journal of Immunotherapy"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0205","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ccell.2016.05.001","article-title":"Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective Fc\u03b3R Engagement","volume":"29","author":"Dahan","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0210","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-017-0504-1","article-title":"Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation","volume":"10","author":"Dai","year":"2017","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0215","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.172.4.2011","article-title":"Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification","volume":"172","author":"Danese","year":"2004","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0220","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.biomaterials.2008.12.004","article-title":"The influence of Ni(II) on surface antigen expression in murine macrophages","volume":"30","author":"D\u2019Ant\u00f2","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0225","first-page":"95","article-title":"Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus","volume":"28","author":"Davis","year":"2001","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/gast.2000.16485","article-title":"Chronic murine colitis is dependent on the CD154\/CD40 pathway and can be attenuated by anti-CD154 administration","volume":"119","author":"De Jong","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0235","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/eji.1830261009","article-title":"CD40 is functionally expressed on human keratinocytes","volume":"26","author":"Denfeld","year":"1996","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0250","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood-2003-10-3684","article-title":"Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells","volume":"105","author":"Dicker","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0245","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood-2006-04-017749","article-title":"CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53","volume":"108","author":"Dicker","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0240","doi-asserted-by":"crossref","first-page":"18008","DOI":"10.1074\/jbc.M300711200","article-title":"CD40-dependent activation of phosphatidylinositol 3-kinase\/Akt pathway mediates endothelial cell survival and in vitro angiogenesis","volume":"278","author":"Deregibus","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0255","doi-asserted-by":"crossref","first-page":"47ra63","DOI":"10.1126\/scitranslmed.3001001","article-title":"Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"2","author":"Duffau","year":"2010","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0260","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0265","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bjh.12630","article-title":"Phase IA\/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma","volume":"164","author":"Fanale","year":"2014","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0270","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4049\/jimmunol.149.2.655","article-title":"Soluble forms of CD40 inhibit biologic responses of human B cells","volume":"149","author":"Fanslow","year":"1992","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0275","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3109\/10428194.2015.1007504","volume":"56","author":"Fayad","year":"2015","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0280","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/09537104.2018.1430358","article-title":"Measuring and interpreting platelet-leukocyte aggregates","volume":"29","author":"Finsterbusch","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0285","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1084\/jem.185.2.341","article-title":"CD40 ligation on human cord blood CD34+ hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells","volume":"185","author":"Flores-Romo","year":"1997","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0290","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2003-04-1244","article-title":"Functional defects of dendritic cells in patients with CD40 deficiency","volume":"102","author":"Fontana","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0295","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2013-02-483586","article-title":"Thiel A. CD40L expression permits CD8+ T cells to execute immunologic helper functions","volume":"122","author":"Frentsch","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0300","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V83.10.2787.2787","article-title":"Inhibition of human B-cell lymphoma growth by CD40 stimulation","volume":"83","author":"Funakoshi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0305","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1172\/JCI119183","article-title":"Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice","volume":"99","author":"Funakoshi","year":"1997","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0310","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/10428190903440946","article-title":"A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia","volume":"51","author":"Furman","year":"2010","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0315","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ni1421","article-title":"Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production","volume":"8","author":"Gallagher","year":"2007","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0320","first-page":"2577","article-title":"Cancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: evidence of preclinical efficacy","volume":"14","author":"Geldart","year":"2004","journal-title":"Proc ASCO"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0325","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.cdd.4401859","article-title":"A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK\/AP-1 activation","volume":"13","author":"Georgopoulos","year":"2006","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0330","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/ATVBAHA.115.307074","article-title":"Lutgens E. Platelet CD40 Exacerbates Atherosclerosis by Transcellular Activation of Endothelial Cells and Leukocytes","volume":"36","author":"Gerdes","year":"2016","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0335","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-08-1360","article-title":"Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells","volume":"15","author":"Gomes","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0340","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/eji.1830250639","article-title":"A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation","volume":"25","author":"Graf","year":"1995","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0345","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1172\/JCI200319301","article-title":"Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions","volume":"112","author":"Grammer","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0350","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00262-018-2236-7","article-title":"A phase I\/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma","volume":"67","author":"Gray","year":"2018","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0355","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.immuni.2004.09.011","article-title":"TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells","volume":"21","author":"Grech","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0360","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/378617a0","article-title":"Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand","volume":"378","author":"Grewal","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0365","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4049\/jimmunol.172.1.231","article-title":"Role of TNF receptor-associated factor 3 in the CD40 signaling by production of reactive oxygen species through association with p40phox, a cytosolic subunit of nicotinamide adenine dinucleotide phosphate oxidase","volume":"172","author":"Ha","year":"2004","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0370","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.4049\/jimmunol.172.9.5297","article-title":"Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro","volume":"172","author":"Hagihara","year":"2004","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0375","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1074-7613(00)80281-2","article-title":"Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells","volume":"6","author":"Hanissian","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0380","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ajt.15591","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study","volume":"20","author":"Harland","year":"2020","journal-title":"American Journal of Transplantation"},{"issue":"10","key":"10.1016\/j.pharmthera.2020.107709_bb0385","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1002\/1521-4141(2001010)31:10<3094::AID-IMMU3094>3.0.CO;2-F","article-title":"Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154","volume":"31","author":"Haswell","year":"2001","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0390","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1073\/pnas.0500187102","article-title":"TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2\/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs","volume":"102","author":"Hauer","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/j.pharmthera.2020.107709_bb0395","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0400","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/35393","article-title":"CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0405","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.V98.4.1047","article-title":"The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40","volume":"98","author":"Henn","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0410","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1182\/blood.V93.9.2999","article-title":"Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand","volume":"93","author":"Hirano","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0415","doi-asserted-by":"crossref","first-page":"15392","DOI":"10.1074\/jbc.M909520199","article-title":"Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling","volume":"275","author":"Hostager","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0420","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1074\/jbc.272.2.911","article-title":"Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes","volume":"272","author":"Hsu","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0425","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","article-title":"A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma","volume":"95","author":"Hussein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0430","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41420-019-0229-8","article-title":"CD40 induces renal cell carcinoma-specific differential regulation of TRAF proteins, ASK1 activation and JNK\/p38-mediated, ROS-dependent mitochondrial apoptosis","volume":"5","author":"Ibraheem","year":"2019","journal-title":"Cell Death Discovery"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0435","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/01.RES.0000070111.98158.6C","article-title":"CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation","volume":"92","author":"Inwald","year":"2003","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0440","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.32141","article-title":"First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies","volume":"145","author":"Irenaeus","year":"2019","journal-title":"International Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0445","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.immuni.2018.03.027","article-title":"Follicular helper cell-germinal center b cell interaction strength regulates entry into plasma cell or recycling germinal center cell fate","volume":"48","author":"Ise","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0450","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1074-7613(02)00394-1","article-title":"The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching","volume":"17","author":"Jabara","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0455","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/intimm\/8.2.275","article-title":"Regulation of CD40 ligand expression on naive CD4 T cells: a role for TCR but not co-stimulatory signals","volume":"8","author":"Jaiswal","year":"1996","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0460","article-title":"Soluble CD40 ligand stimulates CD40-dependent activation of the \u03b22 integrin Mac-1 and protein kinase C zeda (PKC\u03b6) in neutrophils: implications for neutrophil-platelet interactions and neutrophil oxidative burst","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0465","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","article-title":"Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study","volume":"21","author":"Johnson","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0470","doi-asserted-by":"crossref","first-page":"dgz013","DOI":"10.1210\/clinem\/dgz013","article-title":"A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0475","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0480","doi-asserted-by":"crossref","first-page":"eaar6584","DOI":"10.1126\/scitranslmed.aar6584","article-title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity","volume":"11","author":"Karnell","year":"2019","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0485","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1084\/jem.187.2.237","article-title":"Tumor necrosis factor receptor-associated factor 6 (TRAF6) stimulates extracellular signal-regulated kinase (ERK) activity in CD40 signaling along a ras-independent pathway","volume":"187","author":"Kashiwada","year":"1998","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0490","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1073\/pnas.1902145116","article-title":"Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy","volume":"117","author":"Kashyap","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0495","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2036.2005.02526.x","article-title":"Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn\u2019s disease","volume":"22","author":"Kasran","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0500","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.21017","article-title":"CD4+ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets","volume":"43","author":"Khandoga","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0505","first-page":"579","article-title":"Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies","volume":"10","author":"Khubchandani","year":"2009","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0510","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.4049\/jimmunol.155.10.4917","article-title":"Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes","volume":"155","author":"Kiener","year":"1995","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0515","doi-asserted-by":"crossref","first-page":"e31296","DOI":"10.1371\/journal.pone.0031296","article-title":"Preformed CD40L is stored in Th1, Th2, Th17, and T follicular helper cells as well as CD4+ 8- thymocytes and invariant NKT cells but not in Treg cells","volume":"7","author":"Koguchi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0520","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2007-03-081299","article-title":"Preformed CD40 ligand exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell surface in an antigen-specific manner","volume":"110","author":"Koguchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0525","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44245","article-title":"The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets","volume":"8","author":"Koike","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0530","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2003-06-2167","article-title":"Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura","volume":"103","author":"Kuwana","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0535","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1160\/TH04-12-0774","article-title":"The role of CD40 in CD40L- and antibody-mediated platelet activation","volume":"93","author":"Langer","year":"2005","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0540","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.138.3.788","article-title":"Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40)","volume":"138","author":"Ledbetter","year":"1987","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0545","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1084\/jem.20031440","article-title":"CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment","volume":"198","author":"Lee","year":"2003","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0550","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1073\/pnas.96.4.1421","article-title":"Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation","volume":"96","author":"Lee","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0555","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1074-7613(00)80390-8","article-title":"TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival","volume":"7","author":"Lee","year":"1997","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0560","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1182\/blood-2007-01-065482","article-title":"Rapidly induced, T-cell independent xenoantibody production is mediated by marginal zone B cells and requires help from NK cells","volume":"110","author":"Li","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0565","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.intimp.2011.03.021","article-title":"Stimulation-dependent induction of CD154 on a subset of CD4+ FoxP3+ T-regulatory cells","volume":"1","author":"Li","year":"2011","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0570","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2010-01-261206","article-title":"Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis","volume":"116","author":"Lievens","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0575","doi-asserted-by":"crossref","first-page":"e20190673","DOI":"10.1084\/jem.20190673","article-title":"Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis","volume":"217","author":"Lin","year":"2020","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0585","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature13803","article-title":"T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction","volume":"517","author":"Liu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0590","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bjc.2016.42","article-title":"Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients","volume":"114","author":"Loskog","year":"2016","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0595","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/eji.1830261246","article-title":"Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells","volume":"26","author":"Ludewig","year":"1996","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0600","series-title":"Target Organ Toxicology Series","first-page":"131","article-title":"Immunotoxicology and immunopharmacology","author":"Luebke","year":"2007"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0605","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2007-04-084756","article-title":"The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells","volume":"112","author":"Luqman","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0610","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20091293","article-title":"Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile","volume":"207","author":"Lutgens","year":"2010","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0615","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/1471-2164-14-632","article-title":"An expression atlas of human primary cells: inference of gene function from coexpression networks","volume":"14","author":"Mabbott","year":"2013","journal-title":"BMC Genomics"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0620","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/01.CIR.96.2.396","article-title":"Activation of monocyte\/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor","volume":"96","author":"Mach","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-019-1906-x","article-title":"scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold preservation","volume":"21","author":"Madissoon","year":"2019","journal-title":"Genome Biology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0630","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni.2830","article-title":"Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells","volume":"15","author":"Magri","year":"2014","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0635","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1756-8722-6-61","article-title":"An evolving new paradigm: endothelial cells--conditional innate immune cells","volume":"6","author":"Mai","year":"2013","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0640","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.4049\/jimmunol.156.10.3952","article-title":"Activation of human monocytes through CD40 induces matrix metalloproteinases","volume":"156","author":"Malik","year":"1996","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0645","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/j.1460-2075.1990.tb08211.x","article-title":"Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor","volume":"9","author":"Mallett","year":"1990","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0650","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1158\/1078-0432.CCR-10-0385","article-title":"AdCD40L immunogene therapy for bladder carcinoma--the first phase I\/IIa trial","volume":"16","author":"Malmstr\u00f6m","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0655","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1078-0432.CCR-14-0913","article-title":"The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity","volume":"21","author":"Mangsbo","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0660","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.celrep.2018.01.048","article-title":"B1 Cell IgE Impedes Mast Cell-Mediated Enhancement of Parasite Expulsion through B2 IgE Blockade","volume":"22","author":"Martin","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0665","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.1073\/pnas.96.15.8408","article-title":"Crystallographic analysis of CD40 recognition and signaling by human TRAF2","volume":"96","author":"McWhirter","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0670","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/blood-2009-10-250126","article-title":"Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA-secreting plasma cells","volume":"115","author":"Merluzzi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0680","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jaip.2016.09.013","article-title":"Clinical Phenotypes of Hyper-IgM Syndromes","volume":"4","author":"de la Morena","year":"2016","journal-title":"The Journal of Allergy and Clinical Immunology. In Practice"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0675","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.micres.2014.09.003","article-title":"Deciphering the interface between a CD40 receptor and borrelial ligand OspA","volume":"170","author":"Mlynarcik","year":"2015","journal-title":"Microbiological Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0685","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0690","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4049\/jimmunol.174.2.1081","article-title":"TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages","volume":"174","author":"Mukundan","year":"2005","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0695","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/bph.14897","article-title":"The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys","volume":"177","author":"Nicholson","year":"2020","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0700","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.it.2015.04.005","article-title":"Fc\u03b3R dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities","volume":"36","author":"Nimmerjahn","year":"2015","journal-title":"Trends in Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0705","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","article-title":"A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma","volume":"26","author":"Nowak","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0710","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0715","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/ajt.12678","article-title":"Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects","volume":"14","author":"Okimura","year":"2014","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0720","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cancers3010994","article-title":"Role of p53 in Cell Death and Human Cancers","volume":"3","author":"Ozaki","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0725","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature23013","article-title":"TFH-derived dopamine accelerates productive synapses in germinal centres","volume":"547","author":"Papa","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0730","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2008.07039.x","article-title":"The effect of anti-CD40 ligand in immune thrombocytopenic purpura","volume":"141","author":"Patel","year":"2008","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0735","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4049\/jimmunol.158.1.144","article-title":"CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation","volume":"158","author":"P\u00e9guet-Navarro","year":"1997","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0740","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/intimm\/5.2.233","article-title":"A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors","volume":"5","author":"Peitsch","year":"1993","journal-title":"International Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0745","first-page":"1909","article-title":"CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation","volume":"56","author":"Pellat-Deceunynck","year":"1996","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0750","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4049\/jimmunol.160.3.1166","article-title":"IL-12 up-regulates CD40 ligand (CD154) expression on human T cells","volume":"160","author":"Peng","year":"1998","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0755","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.1074\/jbc.271.11.5965","article-title":"Human native soluble CD40L is a biologically active trimer, processed inside microsomes","volume":"271","author":"Pietravalle","year":"1996","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0760","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1183\/09031936.05.00062304","article-title":"Phenotypic characterisation of alveolar macrophages and peripheral blood monocytes in COPD","volume":"25","author":"Pons","year":"2005","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0765","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.1073\/pnas.2032886100","article-title":"Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling","volume":"100","author":"Prasad","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0770","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.jacc.2007.02.044","article-title":"\u2026, Romano M. Homocysteine modulates the CD40\/CD40L system","volume":"49","author":"Prontera","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0775","doi-asserted-by":"crossref","first-page":"37054","DOI":"10.1074\/jbc.M205778200","article-title":"CD40-mediated activation of NF-kappa B in airway epithelial cells","volume":"277","author":"Propst","year":"2002","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0780","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.2194","article-title":"B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen","volume":"13","author":"Puga","year":"2011","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0785","doi-asserted-by":"crossref","first-page":"10168","DOI":"10.1021\/bi9909905","article-title":"High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization","volume":"38","author":"Pullen","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0790","doi-asserted-by":"crossref","first-page":"11836","DOI":"10.1021\/bi981067q","article-title":"CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization","volume":"37","author":"Pullen","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0795","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1002\/eji.200526219","article-title":"The TRAF6, but not the TRAF2\/3, binding domain of CD40 is required for cytokine production in human lung fibroblasts","volume":"35","author":"Purkerson","year":"2005","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0800","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12016-013-8378-7","article-title":"The hyper IgM syndromes","volume":"46","author":"Qamar","year":"2014","journal-title":"Clinical Reviews in Allergy and Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0805","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/eji.1830250203","article-title":"Human circulating specific antibody-forming cells after systemic and mucosal immunizations: differential homing commitments and cell surface differentiation markers","volume":"25","author":"Quiding-J\u00e4rbrink","year":"1995","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0810","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/annrheumdis-2015-eular.4177","article-title":"THU0407 Preclinical Characterization of a Highly Selective and Potent Antagonistic Anti-CD40 mAb","volume":"74","author":"Ralph","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0815","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.163.2.787","article-title":"Activation of the Janus kinase 3-STAT5a pathway after CD40 triggering of human monocytes but not of resting B cells","volume":"163","author":"Revy","year":"1999","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0820","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0825","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","article-title":"Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice","volume":"185","author":"Robles-Carrillo","year":"2010","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0830","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1182\/blood.V94.7.2293.419a27_2293_2300","article-title":"Rapid induction of CD40 on a subset of granulocyte colony-stimulating factor-mobilized CD34(+) blood cells identifies myeloid committed progenitors and permits selection of nonimmunogenic CD40(-) progenitor cells","volume":"94","author":"Rondelli","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0835","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/eji.1830250243","article-title":"Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses","volume":"25","author":"Roy","year":"1995","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0840","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4161\/cbt.10.10.13251","article-title":"Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors","volume":"10","author":"R\u00fcter","year":"2010","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0845","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12967-017-1182-z","article-title":"Adenovirus-mediated CD40L gene transfer increases Teffector\/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients","volume":"15","author":"Schiza","year":"2017","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0850","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40\/CD154 receptor\/ligand dyad","volume":"58","author":"Sch\u00f6nbeck","year":"2001","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0855","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/01.RES.81.3.448","article-title":"Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?","volume":"81","author":"Sch\u00f6nbeck","year":"1997","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0860","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/jcph.1278","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases","volume":"58","author":"Schwabe","year":"2018","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0865","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.11.055","article-title":"Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis","volume":"71","author":"Seijkens","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0870","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.4049\/jimmunol.158.10.4670","article-title":"CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts","volume":"158","author":"Sempowski","year":"1997","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0875","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/pro.5560070506","article-title":"The role of polar interactions in the molecular recognition of CD40L with its receptor CD40","volume":"7","author":"Singh","year":"1998","journal-title":"Protein Science"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0880","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41467-017-01572-7","article-title":"Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain","volume":"8","author":"Singh","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0885","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1074\/jbc.M112.427583","article-title":"Cysteine-rich domain 1 of CD40 mediates receptor self-assembly","volume":"288","author":"Smulski","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0890","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood.V95.12.3758.012k44_3758_3764","article-title":"CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells","volume":"95","author":"Solanilla","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0895","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00262-017-2027-6","article-title":"Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer","volume":"66","author":"Sonpavde","year":"2017","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0900","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4049\/jimmunol.156.1.8","article-title":"Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice","volume":"156","author":"Stout","year":"1996","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0905","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.183.2.693","article-title":"Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion","volume":"183","author":"Stuber","year":"1996","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0910","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.4049\/jimmunol.162.11.6690","article-title":"CD40-CD40 ligand interaction is central to cell-mediated immunity against Toxoplasma gondii: patients with hyper IgM syndrome have a defective type 1 immune response that can be restored by soluble CD40 ligand trimer","volume":"162","author":"Subauste","year":"1999","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0915","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0920","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1161\/ATVBAHA.120.314037","article-title":"Metabolic Reprogramming in Immune Response and Tissue Inflammation","volume":"40","author":"Sun","year":"2020","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0925","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-\u03baB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0930","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/jlb.60.5.651","article-title":"T cell rescue of monocytes from apoptosis: role of the CD40-CD40L interaction and requirement for CD40-mediated induction of protein tyrosine kinase activity","volume":"60","author":"Suttles","year":"1996","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0935","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V100.1.217","article-title":"Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax","volume":"100","author":"Szocinski","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0940","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4049\/jimmunol.1801630","article-title":"Integrin Binding to the Trimeric Interface of CD40L Plays a Critical Role in CD40\/CD40L Signaling","volume":"203","author":"Takada","year":"2019","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0945","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejphar.2013.08.017","article-title":"Histamine inhibits high mobility group box 1-induced adhesion molecule expression on human monocytes","volume":"718","author":"Takahashi","year":"2013","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0955","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3389\/fimmu.2017.01484","article-title":"CD40L Expression Allows CD8+ T Cells to Promote Their Own Expansion and Differentiation through Dendritic Cells","volume":"8","author":"Tay","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0950","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3389\/fimmu.2017.01484","article-title":"CD40L Expression Allows CD8+ T Cells to Promote Their Own Expansion and Differentiation through Dendritic Cells","volume":"8","author":"Tay","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0960","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood.V95.3.1039.003k02_1039_1046","article-title":"CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines","volume":"95","author":"Teoh","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0965","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/eji.1830250152","article-title":"Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1","volume":"25","author":"Tian","year":"1995","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0975","first-page":"148","article-title":"CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation","volume":"88","author":"de Totero","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0970","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1073\/pnas.98.4.1751","article-title":"Regulation of CD40 function by its isoforms generated through alternative splicing","volume":"98","author":"Tone","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0980","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1073\/pnas.96.4.1234","article-title":"Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40","volume":"96","author":"Tsukamoto","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0985","doi-asserted-by":"crossref","first-page":"1322454","DOI":"10.1080\/20013078.2017.1322454","article-title":"Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype","volume":"6","author":"Vajen","year":"2017","journal-title":"Journal of Extracellular Vesicles"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0990","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4161\/rna.6.3.8581","article-title":"Post-transcriptional regulation in lymphocytes: the case of CD154","volume":"6","author":"Vavassori","year":"2009","journal-title":"RNA Biology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb0995","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/hep.25904","article-title":"Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection","volume":"56","author":"Velazquez","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1000","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1093\/emboj\/19.13.3304","article-title":"CD40 signaling in human dendritic cells is initiated within membrane rafts","volume":"19","author":"Vidalain","year":"2000","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ajt.15560","article-title":"A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation","volume":"20","author":"Vincenti","year":"2020","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1010","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/annrheumdis-2018-214729","article-title":"Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"78","author":"Visvanathan","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2003.10.046","article-title":"CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration","volume":"126","author":"Vogel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1020","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1200\/JCO.2001.19.13.3280","article-title":"Phase I study of recombinant human CD40 ligand in cancer patients","volume":"19","author":"Vonderheide","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1035","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/eji.200424973","article-title":"Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys","volume":"34","author":"de Vos","year":"2004","journal-title":"European Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-7-44","article-title":"A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors","volume":"7","author":"de Vos","year":"2014","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1030","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1182\/blood.V92.9.3381","article-title":"Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells","volume":"92","author":"Voorzanger-Rousselot","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S1074-7613(01)00242-4","article-title":"CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines","volume":"15","author":"Wang","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1681\/ASN.V12.1.80","article-title":"CD40 ligation enhances IL-15 production by tubular epithelial cells","volume":"12","author":"Weiler","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1055","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ni.3554","article-title":"TFH cells progressively differentiate to regulate the germinal center response","volume":"17","author":"Weinstein","year":"2016","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccell.2014.11.001","article-title":"Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies","volume":"27","author":"White","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1065","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1182\/blood.V96.9.2917","article-title":"CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia","volume":"96","author":"Wierda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1070","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/leu.2010.191","article-title":"A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154","volume":"24","author":"Wierda","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1075","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/CJI.0b013e31821dcb31","article-title":"Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma","volume":"34","author":"Wilgenhof","year":"2011","journal-title":"Journal of Immunotherapy"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1080","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/annonc\/mdt245","article-title":"A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients","volume":"24","author":"Wilgenhof","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1085","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1681\/ASN.V11112044","article-title":"Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells","volume":"11","author":"Woltman","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1090","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0960-9822(95)00257-0","article-title":"Rapid induction of a novel costimulatory activity on B cells by CD40 ligand","volume":"5","author":"Wu","year":"1995","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/1074-7613(94)90073-6","article-title":"Mice deficient for the CD40 ligand","volume":"1","author":"Xu","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1100","doi-asserted-by":"crossref","first-page":"36083","DOI":"10.1074\/jbc.M113.506220","article-title":"CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner","volume":"288","author":"Yacoub","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1105","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/CIRCRESAHA.116.308750","article-title":"Chronic Kidney Disease Induces Inflammatory CD40+ Monocyte Differentiation via Homocysteine Elevation and DNA Hypomethylation","volume":"119","author":"Yang","year":"2016","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1115","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1084\/jem.182.6.1857","article-title":"Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals","volume":"182","author":"Yellin","year":"1995","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1110","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4049\/jimmunol.152.2.598","article-title":"CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule\/CD40-L. Potential role in regulating helper effector function","volume":"152","author":"Yellin","year":"1994","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1120","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2007-02-076364","article-title":"Natural killer cells trigger differentiation of monocytes into dendritic cells","volume":"110","author":"Zhang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1125","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and Co-inhibitory Pathways in Autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107709_bb1130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002459","article-title":"Platelets Guide Leukocytes to Their Sites of Extravasation","volume":"14","author":"Zuchtriegel","year":"2016","journal-title":"PLoS Biology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820302400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820302400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:00:18Z","timestamp":1778670018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820302400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":225,"alternative-id":["S0163725820302400"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107709","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107709"}}